Gender-Affirming Care for Minors — What the Evidence Shows

“Gender-affirming care” is an umbrella term for a staged series of interventions — social, psychological, and medical — designed to align a young person’s external presentation or physical development with their gender identity. The term is used by the American Academy of Pediatrics, the Endocrine Society, and the World Professional Association for Transgender Health (WPATH). Political rhetoric frequently describes these interventions as “mutilation,” “chemical castration,” or “experimental poison.” Clinical fact-checking requires distinguishing between those claims and the documented medical record.

All major clinical guidelines — WPATH SOC8 (2022), the Endocrine Society (2017), and the AAP (2018, reaffirmed 2023) — recommend a conservative, staged approach. No guideline recommends hormones or surgery for prepubertal children. The staged model is as follows:

Social transition involves using a child’s chosen name, pronouns, clothing, and hairstyle consistent with their gender identity. It is non-medical, fully reversible, and can be adjusted at any time. The AAP describes it as “a supportive involvement” associated with “better mental and physical health outcomes.” Durwood et al. (2017) found that socially transitioned children ages 9–14 reported depression and self-worth levels indistinguishable from cisgender peers.

GnRH analogues (e.g. leuprolide, histrelin) work by binding to pituitary receptors, initially causing a hormone “flare,” then downregulating those receptors to halt production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This stops the gonads from producing estrogen or testosterone, effectively pausing puberty. These medications have been used for decades to treat central precocious puberty in cisgender children — a context in which their safety profile is well-established.

Guidelines recommend blockers starting at Tanner Stage 2–3 (the first physical signs of puberty, typically age 10–13). Their purpose is to prevent irreversible secondary sex characteristics — voice deepening, facial hair, breast development — that cause severe dysphoria and may require surgical correction in adulthood.

A critical safety concern identified by both the Endocrine Society and the Cass Review is the impact on bone mineral density (BMD). During puberty, sex steroids drive bone mineralization. Prolonged blocker use without hormone introduction can result in reduced bone mass accrual. Long-term Dutch cohort data suggests some recovery occurs after starting hormones, though trans-feminine individuals may remain at higher risk for lower lumbar spine BMD.

Cross-sex hormones — testosterone for transmasculine youth, estrogen for transfeminine youth — are introduced in mid-adolescence, typically around age 16, though newer interpretations of guidelines allow earlier initiation with sufficient maturity assessment.

Surgical interventions for minors are extremely rare. When they do occur, they are almost exclusively chest masculinization (“top surgery”) for transmasculine adolescents aged 16–17 with parental consent, typically after at least one year on hormones and thorough psychological assessment. Genital surgeries (“bottom surgery”) are reserved for adults 18+ across all major guidelines. The Rady Children’s Hospital longitudinal study (2025) found significant reductions in depressive symptoms and chest dysphoria following top surgery in 110 transmasculine youth, with high satisfaction rates.

In 2026 the American Society of Plastic Surgeons (ASPS) updated its position, recommending that all gender-related surgeries be delayed until age 19, citing “highly uncertain” benefits and “insufficient evidence” of a favorable risk-benefit ratio for minors. The ASPS noted that surgeons retain an “independent professional responsibility” to assess individual risk beyond institutional referrals. This is a notable departure from earlier practice and represents a significant shift even within the pro-access surgical community.

This staged approach is sometimes misrepresented in media coverage as a single decision. In practice, each step requires separate clinical assessment, informed consent, and — for minors — parental involvement. The vast majority of minors who receive any medical intervention receive only blockers or hormones; surgery for those under 18 is rare and limited almost exclusively to chest masculinization.

Multiple peer-reviewed studies from 2014 through 2025 report a consistent pattern: transgender youth who receive gender-affirming care show significant reductions in depression, suicidality, and gender dysphoria, with improvements in quality of life and psychosocial functioning. The magnitude of these effects is large by psychiatric standards. Below are the key studies, presented with their specific findings, sample sizes, and methodological notes.

A prospective cohort study of 104 transgender and nonbinary youth (ages 12–20) at Seattle Children’s Gender Clinic, with 12 months of follow-up.

Cross-sectional analysis of 20,619 transgender and nonbinary adults from the 2015 U.S. Transgender Survey, examining whether receipt of puberty blockers during adolescence was associated with adult mental health outcomes.

The landmark longitudinal study that became the foundation of global youth gender care. Followed 55 Dutch transgender adults who received puberty suppression in early teens, followed by hormones and surgery under strict criteria (childhood-onset dysphoria, no significant comorbidities).

Durwood et al. (2017, JAACAP) — Socially transitioned transgender children (average age ~11) reported depression and self-worth levels indistinguishable from cisgender controls. Anxiety was slightly elevated but not statistically significant.

Australian National Survey (2025, ScienceDirect) — Analyzing data from 1,697 trans youth (ages 14–21), found that those supported to affirm their gender (medically, legally, or socially) reported significantly less psychological distress, anxiety, self-harm, and suicidal ideation, along with greater happiness.

Journal of Adolescent Health (2025) — In 315 youth (ages 12–20), after six months of hormone therapy, average scores for friendship quality and life satisfaction — which were clinically concerning beforehand — reached healthy levels.

Rady Children’s Hospital (2025, PMC) — Longitudinal study of 110 transmasculine and nonbinary youth found significant reductions in depressive symptoms, gender dysphoria, and chest dysphoria following top surgery, with high surgical satisfaction.

Trevor Project surveys (2021–2025) — Repeated large-scale surveys find that trans youth with access to affirming care report far lower rates of suicide attempts. Youth whose pronouns are consistently respected were 31% less likely to attempt suicide.

The existing evidence is often summarized as a single block (“mental health improves”). But the research shows meaningfully different effect sizes depending on which outcome you examine. Being specific about this is essential for honest evaluation.

Body dysphoria is where the evidence is most consistent. Ascha et al. (2022, JAMA Pediatrics) found significant improvements in chest dysphoria, gender congruence, and body image following top surgery. Ewing et al. (2025) confirmed these reductions in 110 transmasculine youth. Body congruence also appears to be a mediating variable: the 2-year U.S. hormone cohort found that improvements in appearance congruence drove downstream improvements in depression, anxiety, and life satisfaction.

Puberty blockers show a more nuanced pattern than is often claimed. The original Dutch prospective study found decreased depressive symptoms and improved general functioning during suppression, but gender dysphoria and body satisfaction did not significantly change on blockers alone. A 2025 U.S. 24-month study found modest but meaningful emotional stability. The most honest characterization: blockers prevent worsening and create time for assessment rather than producing large immediate mental health gains independently.

Dopp et al. (2025) — a systematic review of 105 studies, the largest available — reaches a conclusion neither side usually acknowledges: the signal across all intervention types is mostly positive, but certainty is low to very low across outcomes. It does not say care doesn’t work. It says the evidence base is methodologically weaker than the effect sizes suggest.

The debate often treats suicidality as though GAC is the primary variable. The research suggests it is considerably more complicated.

The Finnish register study (Ruuska et al. 2024) — already cited elsewhere in this article — found that elevated suicide mortality was no longer statistically significant after accounting for psychiatric treatment history. The primary predictor was psychiatric morbidity, not gender dysphoria by itself. This does not mean discrimination is irrelevant. It means the suicide endpoint is driven heavily by co-occurring mental illness, with social stressors feeding into that.

The best-supported cluster of risk factors across the literature is:

Family support appears as an independent variable of enormous clinical significance. A 2024 JAMA Pediatrics study found that elevated suicide-attempt risk around gender-identity milestones was driven almost entirely by youth in unsupportive families. In supportive family environments, the elevated risk was substantially mitigated.

The clinical implication currently missing from public debate: a treatment can reduce dysphoria, depression, and short-term suicidality without eliminating all suicide risk, because suicide is affected by drivers that medical care alone cannot address. This framing supports both better care and better social support as parallel imperatives, rather than setting up a false binary where care either eliminates suicide risk or “doesn’t count.”

The most influential document in the 2020s shift toward caution. Commissioned by NHS England and led by Dr. Hilary Cass, former President of the Royal College of Paediatrics and Child Health, it oversaw eight systematic reviews of the evidence base for youth gender care. Its final report (April 2024) concluded that the evidence for both puberty blockers and hormones is of “very low” or “low” quality.

The Review made 32 recommendations. Most significantly: puberty blockers should only be available through formal clinical research protocols, gender-affirming hormones should be prescribed with “extreme caution” for under-18s, and psychosocial support should be the first-line treatment. NHS England implemented these recommendations, effectively ending routine puberty blocker prescriptions for minors outside of trials.

The U.S. Department of Health and Human Services released a comprehensive review in 2025 concluding that the overall quality of evidence for medical interventions in minors is “very low” and that the treatments carry “significant risks of permanent harm.” The report explicitly stated there is “no evidence that paediatric medical transition reduces the incidence of suicide” and called for psychosocial support and exploratory psychotherapy as primary approaches rather than routine medicalization.

The Cass Review is the most prominent but not the only evidence assessment to reach cautious conclusions. Three independent systematic reviews from other countries reached similar findings:

Zepf et al. (2024, Germany) — Updated the NICE review using GRADE methodology. Found no new studies on puberty blockers meeting inclusion criteria, and only two low-certainty hormone studies. Concluded that current evidence “doesn’t suggest that gender dysphoria symptoms and mental health significantly improve” with these interventions.

Koener et al. (2025, France) — Independent French systematic review aligned with NICE and Cass findings: evidence for blockers and hormones in minors rated as very low certainty with no clear benefit demonstrated for mental health or dysphoria outcomes.

BMJ Meta-analysis (2024) — Found that puberty blockers consistently suppressed pubertal development (the intended physiological effect) but showed null effect on depression as a mental health outcome. This is the clearest quantitative evidence that the physiological and psychological effects of blockers may be separable — blockers work as designed pharmacologically, but the mental health hypothesis remains unproven.

A high-quality systematic review and meta-analysis corroborated the Cass findings, concluding that the evidence for GAHT in under-26s is “very uncertain” and that the possibility of both benefits and harms cannot be excluded. This review also emphasized that the issue is not just the absence of RCTs but the lack of reliable data from all study designs.

Ruuska et al. (2024, Finland) — A Finnish register study of 23,000 adolescents referred to gender clinics found that while the suicide rate (0.51 per 1,000 person-years) was higher than in peers, this excess vanished after adjusting for psychiatric history. The study found that gender dysphoria itself did not significantly predict suicide once mental illness was accounted for, and that medical transition had no detectable effect on lowering suicide risk.

Finland COHERE (2020) and Sweden — Both countries moved toward restrictive protocols, mandating psychosocial support as first-line treatment and limiting medical interventions to “exceptional cases” of severe, persistent distress. Their rationale: the evidence base does not support routine medical intervention for the broader, more complex patient population now presenting to clinics.

The Cass Review has itself faced significant, peer-reviewed criticism. A major critique published in October 2025 in The Medical Journal of Australia, signed by experts from 15 institutions, argued that the Review “does not guide care for trans young people” and contains “implicit stigma and misinformation,” methodological problems, and conceptual errors.

The King’s College London “Pathways” trial, launched in 2025 to study puberty blockers within an NHS research framework, was paused by the Medicines and Healthcare products Regulatory Agency (MHRA) in February 2026. The MHRA raised concerns about including participants as young as 10 and cited “unquantified risk of long-term biological harms.” This pause reflects the ongoing tension between the need for research and the ethical imperative to “do no harm” when long-term data is missing.

Youth with early-onset gender dysphoria (consistent from age 5–7) who persist into puberty almost universally continue to identify as transgender into adulthood. The Dutch protocol was designed for this specific cohort, and the evidence base is strongest for them. The modern picture is different: the majority of referrals now come from adolescents — particularly natal females — presenting in their teens without a childhood history of gender distress. This shift is the source of much of the current debate.

The Cass Review and European health boards acknowledge this phenomenon. Whether it represents improved social acceptance allowing identification, social influence, or distress manifesting as gender-related (analogous to eating disorders or depression), remains genuinely unresolved. Major medical organizations, including the AAP, reject the “social contagion” framing, describing it as unsupported by evidence.

Transgender youth have 3–6 times the odds of being autistic compared to the general population. This co-occurrence is well-documented and raises genuine clinical questions.

Autistic individuals who have learned to “mask” their neurodivergence may struggle with identity formation, potentially increasing gender questioning. Clinicians may focus on gender dysphoria and miss autism, or vice versa. Critics argue neurodivergent youth may have greater difficulty understanding long-term consequences of medical transition. In practice, guidelines recommend concurrent assessment and treatment of all conditions.

A subtler critique involves the role of expectancy effects. Psychiatrist Alison Clayton and others argue that the mental health improvements seen in the first 12 months of GAC may partly result from a “perfect storm for the placebo effect.”

If a teenager is told by doctors, media, and peers that a treatment is life-saving, receiving it generates psychological relief regardless of biochemical effect (expectation). Clinical attention and sympathy from professionals can improve symptoms independently (Hawthorne effect). Conversely, youth told that delaying treatment leads to suicide may experience worsened symptoms (nocebo effect). Current research cannot fully distinguish these effects from the specific hormonal effect — though the 60–70% reductions in suicidality are large and hard to attribute entirely to placebo.

Older adolescents straddle pediatrics and adulthood. They possess greater cognitive maturity but remain dependent on adult systems. For a 16-year-old who has lived in their affirmed gender for years and undergone thorough assessment, GAHT is often clinically and ethically appropriate. Delaying until 18 is not a neutral option — it means two more years of unwanted pubertal changes.

In the UK, “Gillick competence” allows some 16-year-olds to consent to their own treatment, but recent restrictions have overridden this specifically for gender care, creating legal and ethical limbo. Many 16–17-year-olds referred at 15 face 2–3 year waitlists, aging out of children’s services before being seen, only to join longer adult waitlists.

The benefits of medical care are heavily shaped by social context. A trans teen in a supportive family and school may flourish once care begins; one facing hostility may continue to struggle despite hormones. Social affirmation (correct pronouns, acceptance at home and school) is a powerful independent variable. Trevor Project data shows that youth whose pronouns are respected by all people they live with were 31% less likely to attempt suicide. Benefits of medical care are often inseparable from the psychosocial environment.

The global divergence in youth gender care policy is driven by differing interpretations of the same body of low-quality evidence. The United States, Canada, and Australia follow a primarily affirmative model. The UK, Finland, and Sweden have moved toward a precautionary, research-first model. Both invoke medical ethics and patient welfare.

Harms of denial or delay: Untreated dysphoria typically intensifies through puberty. Blocking puberty late, when unwanted features have already developed, is less effective. Pediatric endocrinologists warn that postponed treatment can lead to underground hormone sources and DIY self-medication, which carry serious safety risks. Self-harm and suicide attempts among trans youth increase in environments with high stigma or restricted care access. Early reports from post-Cass UK suggest rising anxiety among trans youth under the new restrictions.

Risks of intervention: Bone density accrual can be slower on blockers; some reduction in BMD z-scores is documented, though this usually normalizes once sex hormones resume. Fertility is a significant concern: blockers alone do not impair fertility, but if hormones are started without gamete preservation, future fertility may be lost. In practice, clinics offer counseling and sperm/egg banking for older adolescents. Cardiovascular monitoring is required with estrogen. These physical risks must be weighed against the documented risk of suicide without treatment.

The scale of the referral increase across countries is striking. In Denmark, documented gender clinic intakes rose from 4 cases in 2014 to 352 in 2022 — an 8,700% increase in eight years. UK general practice data shows a five-fold rise in recorded transgender identity between 2000 and 2018. An Australian 2021 study reported that 7% of adolescents aged 14–18 identified as trans or gender-diverse, up from 2% in 2018. Whether this reflects genuine prevalence increase, improved social acceptance, or social influence factors remains actively debated. The sharp rise drives much of the precautionary argument: clinics designed for a small, well-defined population are now receiving far more complex cases.

This demographic shift is clinically significant because the Dutch Protocol — the foundational evidence base for youth gender care — was developed with early-onset, predominantly natal male, strictly screened patients with no significant comorbidities. The modern referral population is predominantly adolescent-onset natal females with high rates of autism, depression, anxiety, and trauma. Multiple European health authorities have explicitly cited this mismatch as a reason why the Dutch data does not support routine medicalization of the current cohort.

Detransition is the most politically exploited aspect of the gender-affirming care debate. Critics cite it as proof that transition harms children. Proponents minimize it as vanishingly rare. Both narratives are incomplete. This section presents the peer-reviewed data on detransition rates, reasons, and outcomes — including the methodological problems that make definitive conclusions impossible.

Research in this area is plagued by inconsistent terminology. Five distinct concepts are routinely conflated in media coverage, and separating them is essential for interpreting any statistic.

A person can detransition without regret (viewing it as part of their journey). A person can regret transition without detransitioning. A person can stop hormones for financial or health reasons while still identifying as transgender. And a person can detransition temporarily — then retransition months or years later when circumstances change. The 2015 USTS found that most detransitions were temporary, with the majority later resuming a transgender identity. Studies that fail to distinguish these categories produce misleading headline numbers.

The most politically charged statistic in the gender medicine debate is the claim that 61–98% of gender-dysphoric children “grow out of it.” This figure comes from a small number of older studies — primarily from clinics in Amsterdam and Toronto — that tracked children diagnosed under earlier editions of the DSM. Understanding why these numbers are contested is essential for interpreting the current evidence base.

The DSM criteria problem. Until the DSM-5 was published in 2013, diagnoses of gender identity disorder in childhood used criteria from the DSM-IV and earlier editions. These criteria were broad enough that children could be diagnosed based on gender-nonconforming behavior alone — without necessarily experiencing persistent distress about their sex. A child who preferred cross-sex toys, clothing, or playmates could qualify. The American Psychiatric Association has acknowledged that under the narrower DSM-5 criteria for gender dysphoria (which require clinically significant distress, not merely nonconformity), the persistence rate would likely have been higher.

Gender-nonconforming children in the samples. Critics argue that the older desistance studies included children who, by current standards, would not have been diagnosed with gender dysphoria. However, it is not accurate to say these samples were entirely undiagnosed or entirely gender-nonconforming children. The actual study-level data shows a mix:

So the picture is messier than either side admits. A large share of desisters — between 39% and 68% depending on the study — did meet the full old diagnostic criteria. They were not all just gender-nonconforming kids who wandered into a clinic. But the old DSM-IV criteria were also broader than today’s: they counted cross-dressing, cross-sex roles in play, preference for opposite-sex playmates, and preference for stereotypical games of the other sex, plus one discomfort criterion. A child with strong gender-nonconforming behavior could qualify without necessarily experiencing persistent distress about their sex. A formal academic critique of four key desistance studies concluded that the research focused on cohorts who, by DSM-5 standards, would not all have met criteria for gender dysphoria — but this does not mean none of them would have.

The reanalysis. Even SEGM — the Society for Evidence-Based Gender Medicine, an organization that takes a cautious, pro-precaution stance on youth gender care — acknowledges that the 61–98% range has been critiqued as inflated. SEGM notes that some children diagnosed with “gender identity disorder” were merely extremely gender-nonconforming. A reanalysis focusing only on the subset of children who met full diagnostic criteria found a desistance rate of approximately 67%, with the majority of desisters growing up to be gay adults rather than transgender adults.

The follow-up timing problem. The older studies assumed that individuals not presenting with gender dysphoria by late adolescence could be permanently categorized as cisgender. But an unknown number of those counted as “desisters” may have transitioned later in life — after the study follow-up period ended. This is not a theoretical concern: adult gender clinics regularly see patients who report childhood gender distress that they suppressed during adolescence, only to re-emerge years or decades later.

These figures span a wide range because they measure different things. The 1% surgical regret figure and the 29.8% hormone discontinuation figure are not contradictory — they answer different questions. The critical insight from the Tel Aviv study is that many patients who leave clinics are not detransitioning at all; they are continuing care elsewhere. Equating “loss to follow-up” with “detransition” is a common and serious error in this literature.

For a large majority, detransition is not a reflection of changed identity but a response to hostile circumstances. When safety, finances, or family dynamics improve, most resume transition. For a smaller but significant subgroup, detransition reflects genuine internal shifts: evolving identity, resolution of underlying trauma, health concerns, or the realization that dysphoria had other sources. In surveys of self-identified detransitioners, up to 70% report that mental health conditions or trauma contributed to their initial gender identification. High rates of depression (70%), anxiety (63%), PTSD (33%), ADHD (24%), and autism (20%) have been documented among detransitioners, though the causal direction remains unclear — these conditions may have preceded transition, may have been worsened by it, or may be independent.

Healthcare system factors also contribute. Many detransitioners report that their mental health was not adequately assessed before transition began, that they received insufficient information about long-term risks and alternatives, or that providers lacked experience with detransition entirely. In one study, 55% of detransitioners said they did not receive adequate evaluation. Some describe aging out of pediatric care and having new providers simply renew prescriptions without reassessment, leading them to stop treatment independently. There are currently no widely accepted clinical guidelines for supporting patients through detransition, and most providers have little training in it.

The experiences of people after detransition are varied, and rigorous long-term data is scarce. What evidence exists paints a complex picture across three domains.

Mental health. Some detransitioners report significant improvements in well-being, with decreases in dysphoria and self-harm. Others experience ongoing depression, anxiety, grief, or new forms of distress — particularly when physical changes from transition are irreversible. Many report mixed or evolving feelings: relief about the decision to detransition alongside sadness about permanent bodily changes. No controlled studies exist comparing mental health outcomes between those who continued transition and those who detransitioned.

Physical reversibility. What can and cannot be reversed depends entirely on what interventions were received.

Fertility is a major concern. Cross-sex hormones can impair or eliminate natural fertility, and surgical removal of gonads makes it permanent. If eggs or sperm were not preserved before treatment, detransitioners may face irreversible infertility. Uptake of fertility preservation among trans youth remains low, in part because many adolescents do not fully anticipate wanting biological children later in life.

Social isolation and access to care. Detransitioners often describe a “social vacuum” — feeling excluded from the trans community (where their stories may be perceived as threatening) while also feeling alienated from cisgender peers. Some report that their experiences are co-opted by anti-trans political groups, further isolating them from their former communities. Healthcare access is a consistent barrier: many avoid medical care due to stigma, find that providers have little knowledge of detransition, and lack clear clinical pathways for managing hormone cessation, reversing physical changes, or addressing psychological recovery. Only 24% of detransitioners inform their original providers of their decision.

The current scientific understanding of detransition rates is limited by structural problems that affect the reliability of nearly every figure cited above.

One of the most important questions in this debate is direct: do trans youth who receive gender-affirming care have better outcomes than those who don’t? The answer is “probably yes for mental health in the short term, but the evidence has significant limitations.”

The critical gap: No peer-reviewed study has yet examined outcomes for trans youth in U.S. states that enacted GAC bans versus states that maintained access, controlling for confounders. No study compares outcomes under Finland’s or Sweden’s restrictive protocols versus the U.S./Canadian affirmative model. And no head-to-head trial of psychotherapy-only versus medical intervention exists.

The Trevor Project’s 72% figure is widely cited by advocates but has significant methodological limitations: it is a non-random, self-selected online survey that cannot establish causation. The Tordoff findings are stronger methodologically but limited by small sample size and short follow-up. The Hong Kong study complicates the picture by suggesting social support may matter more than medical intervention — but in an adult population that may not generalize to youth.

Note: "Very Low" GRADE certainty means existing evidence does not reliably support conclusions about net benefit — it does not mean benefit has been disproven. It means the evidence base is too weak to draw confident conclusions in either direction.

The following research would directly address the uncertainties at the center of this debate:

1. Longitudinal registries — Multi-national tracking of youth who initiated transition between 2015 and 2025, following outcomes (mental health, employment, physical health, regret) through their 30s, across both early-onset and adolescent-onset profiles.

2. Comparative psychotherapy trials — Large-scale studies comparing “immediate affirmation” against “standardized exploratory psychotherapy” (as practiced in Finland and Sweden) to determine which yields better outcomes at age 25.

3. Brain and cognitive development — Longitudinal neuroimaging to study the impact of GnRH analogues on adolescent brain maturation, addressing concerns raised by the Cass Review about “unquantified biological harms.”

4. Fertility outcomes — Research on actual utilization and success rates of fertility preservation among 14–17-year-olds, and the degree to which adolescents can grasp the lifelong implications of potential infertility during a dysphoric crisis.

5. Policy impact studies — Comparative research on mental health outcomes in jurisdictions that restrict care (post-Cass UK, US state bans) versus those that maintain affirmative access, controlling for confounders.